Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forest Laboratories and Almirall have filed a new drug application (NDA) for an inhaled antimuscarinic agent aclidinium bromide with the US Food and Drug Administration (FDA) as a treatment for chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
The filing of the NDA was supported by the results of a placebo-controlled, double-blind Phase III trial in which patients were given aclidinium bromide 400 mcg or 200 mcg twice daily or placebo.
The results of the trial showed improvement in morning FEV1 versus placebo at week 12.
In the trial, aclidinium 400mcg twice-a-day was generally well tolerated.
Forest Labs has licensed US rights for aclidinium from Almirall, while Almirall maintains rights for the rest of the world.